Koya Medical secures $26M Series B led by 3×5 Partners to drive innovation in lymphatic and venous care and advance active compression treatments for patients.
Koya Medical Raises $26 Million in Series B Funding Read More »
2021 Brought Breakthrough Device Designation and PMA Process Initiation San Carlos, Calif. (February 1, 2022) – Empirical Spine, Inc., a medical device company creating a new class of spinal implant that works in parallel with the natural structures of the spine to restore functionality and optimize quality of life, achieved several clinical, reimbursement and regulatory
Berkeley, California January. 25, 2022 Channel Medsystems, Inc. a medical device company dedicated to bringing innovation to the delivery of women’s healthcare, today announced that Lisa Garrett has joined the company’s Board of Directors. “Lisa brings a wealth of financial leadership experience at large and emerging companies in the healthcare industry,” said Ric Cote, Chief Executive
Lisa Garrett Joins Channel Medsystems Board of Directors Read More »
Partnership to focus on improving patient outcomes while reducing healthcare system costs of expensive biologic therapeutics SAN DIEGO, CA and LAKELAND, FL – January 4, 2022 – Mindera Health™ and WellDyne have entered into a definitive agreement to improve the management of psoriasis patients with moderate to severe disease using a proprietary dermal biomarker patch
MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD),
MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference. A recording of the fireside chat will be
Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference Read More »
MENLO PARK, Calif.— November 17, 2021— Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery (MIGS) using the OMNI® Surgical System suppressed daily fluctuations in intraocular
Observational studies leverage machine learning to create Mind.PxTM, a test that prospectively predicts biologic class response for individual psoriasis patients with high Positive Predictive Values (PPV) SAN DIEGO, CA – November 16, 2021 – Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis, has announced
Sight Sciences Reports Third Quarter 2021 Financial Results MENLO PARK, Calif., November 10, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended September 30, 2021. Recent Business
Sight Sciences Reports Third Quarter 2021 Financial Results Read More »
MENLO PARK, Calif.— November 10, 2021— Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced that the Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) authorizing the Company to conduct a clinical study to